Profile data is unavailable for this security.
About the company
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
- Revenue in USD (TTM)0.00
- Net income in USD-11.23m
- Incorporated2001
- Employees8.00
- LocationPalisade Bio Inc7750 El Camino Real, Suite 5200CARLSBAD 92009United StatesUSA
- Phone+1 (858) 704-4900
- Fax+1 (302) 697-4597
- Websitehttps://palisadebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Angion Biomedica Corp | 0.00 | -45.86m | 242.05m | 32.00 | -- | 62.59 | -- | -- | -3.15 | -3.15 | 0.00 | 0.2211 | 0.00 | -- | -- | 0.00 | -137.56 | -106.87 | -179.35 | -289.86 | -- | -- | -- | -778.01 | -- | -302.49 | 0.7181 | -- | -- | -- | -47.46 | -- | -18.50 | -- |
| Alector Inc | 21.05m | -142.93m | 243.90m | 103.00 | -- | 7.96 | -- | 11.59 | -1.39 | -1.39 | 0.2043 | 0.2777 | 0.0553 | -- | -- | 204,320.40 | -37.54 | -18.23 | -50.42 | -22.68 | -- | -- | -679.16 | -100.47 | -- | -- | 0.2402 | -- | -79.07 | -0.0503 | -20.06 | -- | -61.79 | -- |
| CapForce Inc | 9.00m | 6.70m | 245.05m | 1.00 | 36.44 | 23.80 | 35.56 | 27.23 | 0.6585 | 0.6585 | 0.8894 | 1.01 | 0.994 | -- | 4.42 | 9,000,000.00 | 75.58 | -74.71 | 81.77 | -111.02 | 100.00 | 30.79 | 76.04 | -602.64 | -- | -- | 0.00 | -- | 52.01 | 8.23 | 134.76 | -- | -- | -- |
| Surrozen Inc | 3.60m | -86.91m | 245.14m | 40.00 | -- | -- | -- | 68.02 | -19.76 | -19.76 | 0.6008 | -2.74 | 0.0507 | -- | 0.4882 | 90,100.00 | -122.36 | -60.48 | -134.33 | -68.26 | -- | -- | -2,411.38 | -993.19 | -- | -- | -- | -- | -- | -- | -47.68 | -- | -55.92 | -- |
| Achieve Life Sciences Inc | 0.00 | -52.35m | 245.94m | 25.00 | -- | 7.26 | -- | -- | -1.38 | -1.38 | 0.00 | 0.6365 | 0.00 | -- | -- | 0.00 | -104.74 | -95.73 | -125.36 | -142.31 | -- | -- | -- | -- | -- | -- | 0.2271 | -- | -- | -- | -33.58 | -- | -- | -- |
| Shattuck Labs Inc | 1.00m | -54.90m | 253.12m | 44.00 | -- | 2.71 | -- | 253.12 | -1.02 | -1.02 | 0.0178 | 1.48 | 0.0094 | -- | -- | 22,727.27 | -51.77 | -32.04 | -56.50 | -35.04 | -- | -- | -5,489.50 | -721.60 | -- | -- | 0.00 | -- | 245.26 | -10.36 | 13.62 | -- | -33.97 | -- |
| OmniAB Inc | 21.09m | -63.67m | 253.36m | 114.00 | -- | 0.9132 | -- | 12.01 | -0.5906 | -0.5906 | 0.1956 | 1.93 | 0.0658 | -- | 6.40 | 185,035.10 | -19.86 | -- | -20.75 | -- | 27.71 | -- | -301.83 | -101.09 | 4.96 | -- | 0.00 | -- | -22.75 | 7.58 | -22.55 | -- | 49.04 | -- |
| Sol Gel Technologies Ltd | 18.97m | -8.99m | 255.12m | 34.00 | -- | 9.80 | -- | 13.45 | -3.23 | -3.23 | 6.81 | 9.34 | 0.4891 | -- | 2.25 | 557,941.20 | -23.17 | -29.32 | -27.70 | -33.19 | -- | -- | -47.37 | -138.22 | -- | -- | 0.00 | -- | 642.47 | -12.81 | 61.16 | -- | -68.01 | -- |
| Palisade Bio Inc | 0.00 | -11.23m | 269.70m | 8.00 | -- | 5.14 | -- | -- | -2.98 | -2.98 | 0.00 | 0.3522 | 0.00 | -- | -- | 0.00 | -137.67 | -130.84 | -221.20 | -165.85 | -- | -- | -- | -31,830.91 | -- | -1,041.55 | 0.0616 | -- | -100.00 | -- | -17.38 | -- | -- | -- |
| Silence Therapeutics plc | 25.81m | -65.01m | 282.46m | 115.00 | -- | 3.35 | -- | 10.94 | -0.462 | -0.462 | 0.1831 | 0.5227 | 0.1383 | -- | 124.98 | -- | -34.83 | -39.00 | -39.01 | -48.09 | 91.20 | 55.91 | -251.86 | -203.50 | -- | -- | 0.00 | -- | 36.71 | 168.26 | 16.45 | -- | 78.99 | -- |
| Amarin Corporation PLC | 226.73m | -86.19m | 289.64m | 275.00 | -- | 0.0316 | -- | 1.28 | -76.48 | -76.48 | 37.99 | 441.28 | 0.3215 | 0.4998 | 1.89 | 824,487.30 | -12.22 | -5.67 | -16.79 | -8.23 | 54.96 | 72.68 | -38.01 | -12.24 | 2.43 | -- | 0.00 | -- | -25.51 | -11.86 | -39.03 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -62.81m | 293.63m | 124.00 | -- | 1.73 | -- | -- | -0.4982 | -0.4982 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -27.27 | -20.34 | -28.36 | -20.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.16 | -- | 18.04 | -- |
| Minerva Neurosciences Inc | 0.00 | -14.03m | 298.59m | 8.00 | -- | -- | -- | -- | -1.85 | -1.85 | 0.00 | -4.94 | 0.00 | -- | -- | 0.00 | -39.57 | -35.73 | -44.01 | -37.64 | -- | -- | -- | -263.85 | -- | -- | 2.36 | -- | -- | -- | 104.80 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Palisade Bio Inc's reporting currency: US Dollar USD
68.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 31 Dec 2025 | 12.05m | 9.85% |
| Commodore Capital LPas of 31 Dec 2025 | 11.45m | 9.35% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 10.54m | 8.61% |
| Point72 Asset Management LPas of 31 Dec 2025 | 10.50m | 8.58% |
| Octagon Capital Advisors LPas of 31 Dec 2025 | 9.57m | 7.82% |
| RA Capital Management LPas of 31 Dec 2025 | 7.12m | 5.82% |
| Columbia Management Investment Advisers LLCas of 31 Dec 2025 | 6.91m | 5.65% |
| Eversept Partners LPas of 31 Dec 2025 | 5.39m | 4.41% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 5.09m | 4.16% |
| Boxer Capital Management LLCas of 31 Dec 2025 | 4.80m | 3.92% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
